Eli Lilly (LLY) is a publicly traded Healthcare sector company. As of July 4, 2026, LLY trades at $1,213.91 with a market cap of $1.08T and a P/E ratio of 52.78. LLY moved +1.74% today. Year to date, LLY is +12.43%; over the trailing twelve months it is +55.77%. Its 52-week range spans $623.78 to $1,238.00. Analyst consensus is strong buy with an average price target of $1,290.79. Rallies surfaces LLY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Eli Lilly Advances Retatrutide; Caps Senior Weight-Loss Drug Costs at $35: Eli Lilly’s investigational triple agonist retatrutide engages GLP-1, GIP and glucagon receptors to potentially exceed current weight-loss efficacy thresholds. The company also unveiled a senior-citizen prescription plan capping monthly out-of-pocket costs for its weight-loss drugs at $35 to expand Medicare patient access.
| Metric | Value |
|---|---|
| Price | $1,213.91 |
| Market Cap | $1.08T |
| P/E Ratio | 52.78 |
| EPS | $23.00 |
| Dividend Yield | 1.73% |
| 52-Week High | $1,238.00 |
| 52-Week Low | $623.78 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $65.18B |
| Net Income | $20.64B |
| Gross Margin | 83.04% |
22 analysts cover LLY: 0 strong buy, 20 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $1,290.79.